Loading stock data…
Merck & Company, Inc. (MRK)
$148.35-1.19 (-0.80%)
Market ClosedLast close Aug 28
Merck & Co., Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Merck & Co., Inc. in the Healthcare sector is trading at $148.35 with a market capitalization of $372.4B. Wall Street consensus targets $148.73 (26 analysts), implying a +0.3% move over the next 12 months. The stock is currently near its 52-week high of $156.92, remaining 28.0% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $16.61B↑ | $16.29B↓ | $16.40B↓ | $17.28B↑ | $15.81B |
| Gross Profit | $12.21B↑ | $12.09B↑ | $10.85B↓ | $13.42B↑ | $12.25B |
| Operating Income | -$433.00M↑ | -$3.20B↓ | $4.07B↓ | $6.55B↑ | $5.55B |
| Net Income | -$1.33B↑ | -$4.24B↓ | $2.96B↓ | $5.79B↑ | $4.43B |
Peer Comparison
JNJUNHPFE
Fundamentals
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bri...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$372.42B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
120.76
Beta
Defensive asset. Lower volatility than the S&P 500.
0.21
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.26%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.57%
Volume
Today's trading volume
8.06M
Recent News
Jim Cramer Says Hold on to Moderna (MRNA) After Phase 3 Cancer Trial
On the August 26 episode of Mad Money, a caller mentioned that they had purchased 1,000 shares of Moderna, Inc. (NASDAQ:MRNA) at $54 a couple of weeks prior, watched the price go up to $150, and asked what they should do. Jim Cramer replied: Here’s what I would do: I think that you have to […]
Did A Product Swap Fuel JNJ Stock’s 54% Surge?
The signs were not in the headline growth rate but in which two products were trading places.
BioNTech Stock Falls on Cancer Vaccine Setback Days After Moderna’s Big Win
BioNTech says it’s ending a Phase 2 trial for its investigational personalized mRNA cancer vaccine. It was being tested to treat colorectal cancer.
Can Merck Stock Outrun Its Pipeline?
Revenue grew at its usual pace over the past year while the stock outran its biggest peers, and the gap sits in a run of clinical readouts that landed early.
BioNTech Terminates Phase 2 Colorectal Cancer Clinical Trial; Shares Fall
BioNTech (BNTX) shares slumped Friday after the company said it is terminating a mid-stage clinical